Synopsis: 

Kate Haviland is the CEO of Blueprint Medicines, a global precision therapy company that creates life-changing medicines for people with cancer and blood disorders. Applying an approach that is both precise and agile, they create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Kate discusses beginning her career at Genzyme before joining Blueprint Medicines, and what the transition to becoming CEO was like after having held various different roles at Blueprint. She also talks about how personalized medicine is transforming patient care, and the company’s focus on applying precision medicine to cancer and hematologic diseases. Finally, she dives into how the current environment informs how she approaches leading a publicly traded biotech and her perspective on partnerships.

Interested in learning more? Check out their recent approval here: https://rb.gy/4126e

Biography: 
Kate brings an impressive breadth of experience and leadership within the biopharmaceutical industry, as well as a substantial background in business development, commercial and strategic planning, and program management. Since April 2022, Kate has served as Chief Executive Officer of Blueprint Medicines. Kate joined Blueprint in 2016 as Chief Business Officer and later served as Chief Operating Officer, where she served as the founding chair of the portfolio management team, formed and executed business development strategy, drove global capital investment plans, and played a key role in capital market financings. In addition, she worked to drive the transformative growth of the company and support its evolution into a fully integrated business by developing and providing ongoing management of critical functions, including portfolio strategy, corporate development, commercial strategy, international, technical operations, corporate affairs, and information systems. Prior to joining Blueprint Medicines, Kate held leadership roles focused on building emerging, high-growth companies and advancing the development of innovative therapies in oncology and rare diseases as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals, Head of Commercial Development at Sarepta Therapeutics, Executive Director of Commercial Development at PTC Therapeutics, and roles in both corporate development and project management at Genzyme. She holds a B.A. from Wesleyan University with a double major in Biochemistry/Molecular Biology and Economics and an M.B.A. from Harvard Business School. Kate currently serves as chair of the board of directors at Fulcrum Therapeutics and is a member of the audit and compensation committees.

Pioneering precision therapies for cancer & blood disorders, Kate Haviland, CEO, Blueprint Medicines

Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.

New tracks tagged #HEME